Plain-English translation of NCT07079631 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This clinical trial is testing whether , a new investigational medication, combined with another new medication called and standard chemotherapy, can help treat metastatic colorectal cancer (cancer that has spread beyond the colon or rectum). The trial will first determine safe doses of these medications when given together, and then test whether this combination works better than current standard treatments in slowing or shrinking tumors.
Current treatments for advanced colorectal cancer that has spread do not work for all patients, and some patients eventually stop responding to standard chemotherapy. This trial is exploring whether combining these new medications with chemotherapy might help more patients by attacking the cancer in different ways.
You likely qualify if…
You likely don't qualify if…
You will go through a screening period to confirm your eligibility, then enter the treatment phase where you will receive the study medications and chemotherapy (timing and schedule determined by the trial). Most participants stay in active treatment for about 6 to 10 months on average, continuing until the cancer worsens, you cannot tolerate the treatment, or the study ends. After that, you will be monitored regularly for survival and any long-term side effects, even after you stop the active treatment.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States
Germany